Wall Street analysts expect that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will post ($1.00) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Adamas Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.82) and the lowest estimate coming in at ($1.15). Adamas Pharmaceuticals reported earnings of ($1.26) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 20.6%. The business is expected to report its next earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year earnings of ($3.87) per share for the current year, with EPS estimates ranging from ($4.56) to ($3.46). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.32) per share, with EPS estimates ranging from ($2.80) to ($1.50). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.05. Adamas Pharmaceuticals had a negative net margin of 291.22% and a negative return on equity of 122.40%. The firm had revenue of $11.67 million for the quarter, compared to analyst estimates of $12.78 million.
Several equities analysts have commented on the stock. Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine lowered shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Mizuho reissued a “sell” rating and issued a $5.00 target price on shares of Adamas Pharmaceuticals in a report on Wednesday, April 24th. Piper Jaffray Companies set a $23.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 5th. Finally, HC Wainwright set a $40.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 5th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. Adamas Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $20.25.
In related news, CEO Gregory T. Went sold 6,319 shares of Adamas Pharmaceuticals stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $7.99, for a total transaction of $50,488.81. Following the sale, the chief executive officer now directly owns 176,291 shares of the company’s stock, valued at approximately $1,408,565.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 8,361 shares of company stock worth $66,816 over the last ninety days. 24.90% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in ADMS. Dimensional Fund Advisors LP purchased a new stake in Adamas Pharmaceuticals during the 3rd quarter valued at approximately $2,209,000. MetLife Investment Advisors LLC raised its stake in Adamas Pharmaceuticals by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 16,709 shares of the specialty pharmaceutical company’s stock valued at $335,000 after acquiring an additional 5,940 shares during the last quarter. Teachers Advisors LLC raised its stake in Adamas Pharmaceuticals by 68.7% during the 3rd quarter. Teachers Advisors LLC now owns 61,024 shares of the specialty pharmaceutical company’s stock valued at $1,222,000 after acquiring an additional 24,859 shares during the last quarter. Vanguard Group Inc. raised its stake in Adamas Pharmaceuticals by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,008,448 shares of the specialty pharmaceutical company’s stock valued at $20,189,000 after acquiring an additional 18,879 shares during the last quarter. Finally, Vanguard Group Inc increased its position in Adamas Pharmaceuticals by 1.9% during the 3rd quarter. Vanguard Group Inc now owns 1,008,448 shares of the specialty pharmaceutical company’s stock worth $20,189,000 after purchasing an additional 18,879 shares during the period. 84.76% of the stock is currently owned by institutional investors.
ADMS stock traded down $0.06 during mid-day trading on Friday, hitting $4.99. The stock had a trading volume of 488,018 shares, compared to its average volume of 523,691. The company has a quick ratio of 6.86, a current ratio of 7.03 and a debt-to-equity ratio of 2.00. Adamas Pharmaceuticals has a 52 week low of $4.93 and a 52 week high of $29.49. The firm has a market cap of $137.39 million, a P/E ratio of -1.02 and a beta of 1.35.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Read More: Gap Up Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.